Patient-reported Outcomes in the Treatment of Schizophrenia
Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
October 3, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2006
CompletedSeptember 12, 2013
September 1, 2007
8 months
September 12, 2005
September 11, 2013
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Participate in S1543003 and S1543004 in the U.S. sites
You may not qualify if:
- Participate in S1543003 and S1543004 other than U.S. sites
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Director Solvay
Solvay Pharmaceuticals
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 12, 2005
First Posted
October 3, 2005
Study Start
May 1, 2005
Primary Completion
January 1, 2006
Last Updated
September 12, 2013
Record last verified: 2007-09